Protai is an AI-powered drug discovery startup that integrates deep proteomics with machine learning to revolutionize the development of new therapies. By analyzing proteins in their native states, Protai aims to transform disease treatment by identifying unique disease drivers and developing innovative strategies for breakthrough therapies and improved patient outcomes. Key Features and Functionality: - AIMS™ Platform: Protai's proprietary drug discovery engine combines structural and functional mass spectrometry proteomics data with AI to uncover novel drug mechanisms and identify best-in-class drug candidates. - Target Redefinition: The platform maps disease-specific protein states to define precise, context-specific mechanisms of action, enabling selective inhibition of disease-relevant activities while preserving beneficial functions. - Structural Modeling: Utilizing structural proteomics techniques like cross-linking mass spectrometry (XL-MS) and hydrogen-deuterium exchange mass spectrometry (HDX-MS), AIMS™ determines disease-specific protein conformations. These are then modeled using structural AI to identify pockets suitable for targeted drug design. - Computational Drug Design: The platform facilitates the discovery of modulators for redefined targets in oncology and immunology, accelerating the development of precision medicines. Primary Value and Problem Solved: Protai addresses the challenges in drug discovery by providing a comprehensive understanding of protein networks and their dynamic interactions in health and disease. This approach allows for the identification of unique disease drivers and the development of targeted therapies, leading to more effective treatments and improved patient outcomes. By integrating proteomics with AI, Protai enhances the precision and efficiency of drug discovery, reducing the time and cost associated with bringing new drugs to market.